Abstract
Sudden cardiac death (SCD) remains an unsolved problem in the twenty-first century. It is often due to rapid onset, ventricular arrhythmias caused by a number of different clinical conditions. A proportion of SCD patients have identifiable diseases such as cardiomyopathies, but for others, the causes are unknown. Viral myocarditis is becoming increasingly recognized as a contributor to unexplained mortality, and is thought to be a major cause of SCD in the first two decades of life. Myocardial inflammation, ion channel dysfunction, electrophysiological, and structural remodeling may play important roles in generating life-threatening arrhythmias. The aim of this review article is to examine the electrophysiology of action potential conduction and repolarization and the mechanisms by which their derangements lead to triggered and reentrant arrhythmogenesis. By synthesizing experimental evidence from pre-clinical and clinical studies, a framework of how host (inflammation), and viral (altered cellular signaling) factors can induce ion electrophysiological and structural remodeling is illustrated. Current pharmacological options are mainly supportive, which may be accompanied by mechanical circulatory support. Heart transplantation is the only curative option in the worst case scenario. Future strategies for the management of viral myocarditis are discussed.
Introduction
Viral myocarditis is myocardial inflammation due to a viral infection. It is thought to be a major cause of sudden cardiac death (SCD) in the pediatric and adolescent population (Steinberger et al., 1996). Indeed, one study found that infants who suffered from SCD had mild fever and insomnia several days prior to their deaths, suggesting infection as a major contributor in this group (Gaaloul et al., 2016). At least 20 viruses have been implicated in myocarditis, but the commonest virus involved are Parvovirus B19 (PVB19), human herpes virus 6, adenovirus and coxsackievirus B3 (CVB3; Gaaloul et al., 2012). Table 1 summarizes the known virus strains, gene/protein targets, and estimated prevalence. Not all viral infections are the same: cardiotropic viruses are known to infect >90% of the human population, yet only 1–5% of these will develop viral myocarditis as proven histologically (Andreoletti et al., 2009). Patients can take a varied clinical course, from acute to chronic inflammation involving focal or diffuse areas of the myocardium (Fung et al., 2016). Figure 1 illustrates demonstrates the histology from a case of viral myocarditis due to PVB19, characterized by diffuse interstitial myocardial inflammatory infiltrate composed of CD68 positive macrophages, CD3 lymphocytes in an interstitial and perivascular distribution with minimal necrosis (Tavora et al., 2008). Some have insidious onset with limited inflammation, others undergo fulminant course with overwhelming inflammation or develop chronic heart failure from an autoimmune-mediated process (Heymans, 2006). There are some genetic predispositions, making some individuals more susceptible to viral myocarditis. For example, the commonest polymorphism for the KCNQ1 gene encoding for the slow inactivating K+ channel in Asians, appears to be protective against viral-induced arrhythmias (Steinke et al., 2013). Not all viruses are the same: some viruses such as CVB3 and adenovirus serotype 5 can induce more severe viral myocarditis (Savon et al., 2008; Valdes et al., 2008). For the post-mortem of infants suffering from SCD, only a minority of cases showed features of myocardial inflammation (Gaaloul et al., 2012), suggesting contributing factors, such as signals initiated by the viruses leading to ion channel dysfunction or electrophysiological and structural remodeling, to arrhythmogenesis. Fundamentally, viruses must have some means of subverting the host's machinery for their replication to ensure their own survival. This can be achieved by using the host's signaling mechanisms or the mircroRNA (miRNA) system to target the host's messenger RNAs for translational repression and degradation (Tomari and Zamore, 2005). The aim is to shut down the host's protein translation machinery and enhance viral pathogenicity or replication (Orom et al., 2008; Hemida et al., 2013; Tong et al., 2013; Ye et al., 2013). As we shall see later, altered cellular signaling, such as activation of kinases and enzymes, and upregulation of miRNAs, can lead to ion channel remodeling that can potentially reduce the threshold for arrhythmogenesis. Thus, the host's immune response or viral factor can induce electrophysiological or structural remodeling, resulting in action potential (AP) conduction or repolarization abnormalities to promote arrhythmogenesis (Figure 2; Tse and Yeo, 2015).
Table 1
| Virus | Type | Host target | Estimated prevalence | References |
|---|---|---|---|---|
| Adenovirus | dsDNA | Common Coxsackievirus B-adenovirus receptor | 8–23% | Bergelson et al., 1997; Bowles et al., 2003; Kühl et al., 2005; Andreoletti et al., 2009 |
| Coxsackievirus | ssRNA | CD55, Common Coxsackievirus B-adenovirus receptor | 2 to 50% (Up to 46% after transplantation) | Arbustini et al., 1992; Bergelson et al., 1997; Martino et al., 1998; Bowles et al., 2003; Andreoletti et al., 2009 |
| Cytomegalovirus | dsDNA | Heparan Sulfate Proteoglycans, PDGFRα, EGFR, and integrin heterodimers | 0.8–3% | Bowles et al., 2003; Chan et al., 2012 |
| Echovirus | ssRNA | Human very late antigen 2 (VLA-2) | 10.5% | Hughes et al., 2003; Kühl et al., 2005 |
| Enterovirus | ssRNA | Enteroviral protease 2A directly cleaves dystrophin | 8–32.6% | Badorff et al., 1999; Bowles et al., 2003; Kühl et al., 2005 |
| Epstein-Barr virus | dsDNA | Increased latent membrane protein 1 is expressed in EBV latent cells | 0–6% | Karjalainen et al., 1983; Bowles et al., 2003; Chimenti et al., 2004 |
| Hepatitis B virus | dsDNA | Enters injured endothelium | <1% | Reis et al., 2007; Rong et al., 2007 |
| Hepatitis C virus | ssRNA | CD68 (monocytes and macrophages) | 2.9–3.8% | Matsumori et al., 2000; Reis et al., 2007; Matsumori, 2012 |
| Herpes simplex virus | dsDNA | <1% | Bowles et al., 2003 | |
| Human herpes virus 6 | dsDNA | ?NK cells; infects endothelium | 8–10.5% | Yoshikawa et al., 2001; Caruso et al., 2002; Kühl et al., 2005; Andreoletti et al., 2009 |
| Human immunodeficiency virus 1 and 2 | ssRNA | Gp120 | Common in HIV positive patients | Shaboodien et al., 2013 |
| Influenza virus | ssRNA | Ectopic trypsins | 1.7–10% (up to 10% patients in influenza pandemics) | Bowles et al., 2003; Rezkalla and Kloner, 2010; Pan et al., 2011; Ukimura et al., 2012 |
| Mumps virus | ssRNA | Up to 15% of mumps cases before introduction of vaccine (associated with endocardial fibroelastosis) | Rosenberg, 1945; Arita et al., 1981 | |
| Parvovirus B19 | ssDNA | B19 receptor (erythrocyte P antigen) | 1–36.6% | Porter et al., 1988; Bowles et al., 2003; Kühl et al., 2005; Andreoletti et al., 2009 |
| Polio virus | ssRNA | Up to 40% of cases of poliomyelitis | Laake, 1951 | |
| Rabies virus | ssRNA | Invasion of neural tissue or blood cells | ? | Ross and Armentrout, 1962; Cheetham et al., 1970; Venkat Raman et al., 1988; Liao et al., 2012 |
| Respiratory syncytial virus | ssRNA | ? | <1% | Huang et al., 1998; Bowles et al., 2003; Eisenhut, 2006 |
| Rubella virus | ssRNA | ? | ? | Ainger et al., 1966; Kriseman, 1984 |
| Vaccinia virus (smallpox vaccine) | dsDNA | ? | <1–9.5% | Karjalainen et al., 1983; Casey et al., 2005 |
| Varicella virus | dsDNA | ? | ? | Woolf et al., 1987; Rich and McErlean, 1993; Alter et al., 2001; Biocic et al., 2009; De et al., 2011 |
The prevalence of different viruses was obtained from Kühl et al. (2005) and Andreoletti et al. (2009).
? - Information not available.
Figure 1
Figure 2
Arrhythmogenesis can arise from AP conduction or repolarization abnormalities
Mechanisms of arrhythmias can be divided into triggered activity and reentry (Figure 3; Tse, 2015; Tse et al., 2016m). Triggered activity arises from either early or delayed afterdepolarization phenomena (EADs and DADs), which are depolarization events occurring before the next AP. Normally the repolarization phase is determined by a balance of inward currents mediated by the Na+-Ca2+ exchanger (INCX) and L-type Ca2+ channels (LTCC, ICa, L), and outward currents mediated by a number of K+ channels (IKr, IKs, IK1,IK, ATP; Nerbonne, 2000; Tse et al., 2016j). Prolongation in action potential duration (APD) can result in LTCC reactivation, typically during phase 2 or phase 3 of the AP, leading to EADs (January et al., 1988). By contrast, DADs can develop under conditions of intracellular Ca2+ overload (Priori and Corr, 1990). This involves spontaneous release of Ca2+ from the sarcoplasmic reticulum via the ryanodine receptors (RyRs) and subsequent activation of the Na+-Ca2+ exchanger (NCX). Both EADs and DADs can therefore result in membrane depolarization, and if these are of sufficient amplitude, triggered activity can be elicited.
Figure 3
Reentry involves re-activation of the myocardium that has recovered from refractoriness, and may involve an obstacle for the circus-type, or without an obstacle in phase 2 reentry (Tse et al., 2016d). Circus-type reentry requires three conditions: reduced conduction velocity (CV) of the AP wave, so that the tissue ahead remains excitable, unidirectional conduction block to prevent APs traveling in opposite directions from extinguishing, and an obstacle (which can arise dynamically or be a fixed structural defect) around which the AP is able to circulate (Tse, 2015). Thus, a decrease in the wavelength of excitation (λ) given by the product of CV and reduced effective refractory period (ERP), would predispose to reentry (Smeets et al., 1986; Vaidya et al., 1999; Osadchii, 2010, 2014; Tse et al., 2012, 2016e,f,g,k,o).
Of these parameters, CV of the APs traveling through the myocardium, traditionally described by the core conductor theory, depends on both passive and active membrane properties (Tse and Yeo, 2015; Tse et al., 2016d). Passive properties refer to the biophysical parameters of axial resistance (ri), extracellular resistance (ro) and membrane capacitance (cm). The existence of electrical communication pathways between successive cardiomyocytes was shown, mediated by gap junctions (Spray and Burt, 1990). Six connexin (Cx) subunits make up a connexon and two connexons make up a gap junction. Since the discovery of gap junctions, it has been assumed that their electrical coupling is the primary mechanism by which cardiac conduction occurs. However, this is in conflict with experiments in heterozygous Cx43+∕−− mice, which showed 45–50% reduction in Cx43 expression, but CV was either unaltered (Morley et al., 1999; Vaidya et al., 2001; van Rijen et al., 2004; Stein et al., 2009, 2011; George et al., 2015) or reduced by 23–44% (Guerrero et al., 1997; Thomas et al., 1998; Eloff et al., 2001). This suggests other mechanisms, such as ephaptic coupling, may have an important role in mediating cardiac conduction (Rhett and Gourdie, 2012; Lin and Keener, 2013, 2014; Rhett et al., 2013; Veeraraghavan et al., 2014a,b,c, 2015; George et al., 2015). This is clinically relevant because interstitial edema can increase extracellular volume, thereby reducing CV (Veeraraghavan et al., 2012).
Active properties refer to the voltage-gated conductance responsible for the AP upstroke, namely the Na+ channels. The effective refractory period (ERP) is the time over which Na+ channels are inactivated and cannot open again. They can be reactivated when the membrane potential is restored to the resting value. Thus, APD usually approximates ERP, i.e., a shorter repolarization time course usually leads to shorter ERP. When APDs are prolonged, sudden increase in heart rate can engage the steep portion of APD restitution curve, producing APD alternans, unidirectional conduction block, wave break and reentry (Hsieh et al., 2009, 2014, 2016; Tse et al., 2016m). Phase 2 reentry simply involves a difference in APD between two electrically connected regions, where conduction of the action potential dome from sites where it is maintained to sites where it is abolished can then result in an extrasystole (Shimizu et al., 2005). This is thought to underlie reentrant arrhythmogenesis in Brugada syndrome, and may be relevant in patients suffering from viral myocarditis with an unmasked Brugada phenotype.
Host-mediated and viral-induced inflammation and can promote arrhythmogenesis by inducing ion channel abnormalities and cardiac remodeling
All of the above factors governing conduction or repolarization can be affected by myocardial inflammation or changes induced by the viruses to promote arrhythmogenesis. Thus, in a rat model of immune-mediated myocarditis, increased oxidative stress and inflammation can increase the release of inflammatory cytokines such as tumor necrosis factor-α and interleukin-6, leading to Ca2+/calmodulin Protein Kinase II (CaMKII) activation. This can phosphorylate the Ca2+ release channel, ryanodine receptor 2 (RyR2), to increase abnormal Ca2+ release from the sarcoplasmic reticulum (Tse et al., 2016n). Moreover, there is greater Ca2+ entry from the extracellular space (Tominaga et al., 1993). Both would lead to increased duration of Ca2+ transient, which would in turn prolong APD due to positive -APD coupling (Park et al., 2014a,b). This led to triggered activity, presumably via development of EADs, although DADs are also possible due to abnormal Ca2+ release. Regional differences in Ca2+ transients can also increase the heterogeneity in repolarization and produce arrhythmogenic APD alternans. In a rat model of autoimmune myocarditis, several ion channels mediating the fast transient outward (Ito, f) and delayed rectifier (IKr) currents were downregulated (Saito et al., 2002; Wakisaka et al., 2004). This led to prolongations of both ERP and APD, the latter being responsible for EADs and triggered activity. Similar reduction of repolarizing currents leading to APD prolongation has also been observed in mice with autoimmune myocarditis (Tang et al., 2007). Inflammation can also promote changes in the extracellular matrix (ECM). Thus, ECM composition is regulated by matrix metalloproteinases (MMPs), which are normally inhibited by tissue inhibitors of matrix metalloproteinases (TIMPs; Pauschinger et al., 2004). MMP activation during acute myocarditis can tip the balance toward ECM remodeling, in turn causing fibrosis. This would reduce CV by disrupting cardiomyocyte-cardiomyocyte coupling or increasing fibroblast-cardiomyocyte coupling, increasing ri and Cm, respectively (Tse and Yeo, 2015). Moreover, viral myocarditis predisposes to the development of dilated cardiomyopathy (DCM), which itself is arrhythmogenic. Interested readers are directed to this excellent article here for further discussion on the mechanisms by which myocardial infections by cardiotropic viruses lead to DCM and heart failure (Baksi et al., 2015).
Viruses can also alter the function or expression of ion channels or induce structural remodeling of the myocardium. CVB3 can increase the ICa, leading to APD prolongation (Steinke et al., 2013). It also increases IKr and IKs initially but decreases them in the longer term, leading to APD shortening and prolongation, respectively. CVB3 can upregulate miR-1, which in turn disrupts cardiomyocyte-cardiomyocyte coupling by translational repression of the gene GJA1, which encodes for connexin-43 (Cx43; Xu et al., 2012). Together, these changes induced by CVB3 would produce Ca2+ overload and induce abnormalities in action potential repolarization and conduction, predisposing to both triggered activity and reentry. The cardiotropic PVB19 appears to target endothelial cells as opposed to cardiomyocytes (Bultmann et al., 2003). Since endothelial cells are found in the heart and can communicate with the adjacent cardiomyocytes, endothelial dysfunction may indeed be responsible for cardiac remodeling during inflammation. PVB19 a pro-apoptotic protein called viral protein NS1, which can activate caspase 3, leading to the degradation of the Na+/H+ exchanger (Lupescu et al., 2009). Its B19 minor capsid protein VP1 has intrinsic phospholipase A2 activity, which can increase the activity of Ca2+ release-activated Ca2+ channel (ICRAC), which is normally responsible for capacitative, store-operated Ca2+ entry by increasing ICa (Lupescu et al., 2006). PLA2 activity of VP1 is thought to underlie downregulation of Na+/K+-ATPase and a number of K+ channels (mediating IKr and inward rectifying currents, IKir; Almilaji et al., 2013; Ahmed et al., 2014, 2015).
Finally, there may be interaction between genetic predisposition of ion channel dysfunction and viral myocarditis (Salerno et al., 2011; Juhasz et al., 2014). In a case series, patients who suffered from viral myocarditis complicated by ventricular fibrillation showed electrocardiographic features of Brugada, early repolarization and short QT syndromes (Salerno et al., 2011). Interestingly, not only were ventricular arrhythmias observed during the acute phase of the myocarditis but persistent ECG changes were observed after the inflammation has subsided, suggesting underlying abnormalities in ion channel function, predisposing to arrhythmogenesis during myocarditis. Indeed, as pointed out by these authors (Salerno et al., 2011), this could be due to temperature-dependent alterations in ion channel function (Pasquié, 2005). This notion is consistent with previous observations that infants suffering from SCD had mild fever before their deaths (Gaaloul et al., 2016), which would suggest fever as a trigger of the arrhythmia (Pasquié, 2005). This is also in keeping with previous associations between exacerbation of a Brugada pattern and a febrile state (Patane and Marte, 2010; Patane et al., 2010).
Current management options and future therapy
Diagnosis of viral myocarditis can be difficult, and requires a series of investigations. Blood tests may reveal cardiac damage as reflected in raised troponins and high sensitive C-reactive protein assays (Guo, 2008). Polymerase chain reaction (PCR) can be used to detect viral nucleic acid materials for confirming a specific viral infection. Electrocardiography is non-specific, but can reveal conduction block, ST segment elevation or T wave abnormalities. Ventricular tachycardia or fibrillation may be observed. Echocardiography is used to determine ventricular function and rule out non-viral causes of heart failure, and can distinguish between acute from fulminant myocarditis (Felker et al., 2000). Cardiac magnetic resonance imaging is excellent for characterizing structural abnormalities, such as areas of fibrosis by late gadolinium enhancement (Vassiliou et al., 2014; Tse et al., 2015a,b) It is highly valuable in the diagnosis of myocarditis because it can detect interstitial edema during acute inflammation and fibrosis from a reparative process (Babu-Narayan et al., 2007; Petryka et al., 2014; Baksi et al., 2015). Interstitial edema reflects increased extracellular fluid volume, which would reduce CV by an ephaptic mechanism. Traditionally, the confirmatory test for diagnosing viral myocarditis was endomyocardial biopsy, which can be guided by electro-anatomical mapping to reduce the likelihood of false negatives. The criteria is a value more than 14 leukocytes/mm2 and a T-lymphocyte count of more than 7 cells/mm2 (Basso et al., 2013). However, due to advances in CMR technology, the use of biopsy is now limited when giant cell myocarditis is suspected.
For arrhythmic risk stratification, using different indices based on ECG parameters have been used for congenital arrhythmic syndromes and heart failure (Tse, 2016a,b,c; Tse and Yan, 2016a,b), but not for viral myocarditis. CMR can be used for stratifying patients into low and high risk group for developing ventricular arrhythmogenesis by quantifying the amount of interstitial edema and fibrosis, which would guide monitoring and therapy (Strauss and Wu, 2009; Mavrogeni et al., 2013; Baksi et al., 2015; Kallianos et al., 2015; Neilan et al., 2015; Sanguineti et al., 2015; Anzini et al., 2016).
The major problem of viral myocarditis is the limited number of drugs available for modifying the course of the disease and preventing the arrhythmic complications (Kindermann et al., 2012). The current treatment is supportive, using medications such as angiotensin converting enzyme inhibitors, beta blockers and spironolactone. Anti-arrhythmic agents are used when ventricular arrhythmias are observed. Mechanical circulatory support is potentially life-saving by allowing an interval for the return of heart pumping function or providing a bridge to heart transplantation, which may be required in the worst case scenario (Duncan et al., 2001). Other suggested approaches are immunosuppression, immunoglobulin, immunoadsorption, and anti-viral treatment (Jensen and Marchant, 2016). However, immunosuppressive therapy should be limited to giant cell myocarditis and lymphocytic myocarditis. The use of intravenous immunoglobulin is not recommended currently. There is a pressing need for drug development, and novel therapeutic agents that can reduce viral entry into cardiomyocytes, and viral-induced or host-mediate myocardial inflammation, which would reduce the arrhythmic burden in this patient population.
The use of animal models has advanced our understanding of the mechanisms of arrhythmias and provide a platform for assessing the efficacy of pharmacological therapy (Chen et al., 2016; Choy et al., 2016; Tse et al., 2016a,b,c,h,i,l). Thus, pre-clinical mouse studies have demonstrated the efficacy of Chinese medicinal extracts such as QiHong and Qishaowuwei formula in suppressing viral attachment and penetration, which significantly ameliorated CVB3-induced myocardium necrosis (Song et al., 2007; Fengqin et al., 2010). The benefits of traditional Chinese medicines in viral myocarditis thus warrant further investigation. Other novel therapies include mutation of the viral genome to induce the expression of cytokines, such as interferon-gamma, which can modulate the immune responses and prevent inflammation (Henke et al., 2008). Modulation of ion channel function may be useful for anti-arrhythmic therapy. Triggered activity can be suppressed by reversing APD prolongation and/or Ca2+ overload. Thus, EADs can be inhibited the late INa (Belardinelli et al., 2013), whereas DADs could be abolished by blocking RyR2 (Savio-Galimberti and Knollmann, 2015) or NCX (Sipido et al., 2006). KATP channel openers such as mexiletine, with previously demonstrated cardioprotective effects during ischaemia, could suppress APD prolongation during acute myocarditis and may therefor protect against Ca2+ overload, DADs and spatial heterogeneities in APDs (Niwano et al., 2012).
In conclusion, viral myocarditis is an important cause of mortality especially in infants, adolescents and young adults, predisposing to life-threatening cardiac arrhythmias. Current drug options are inadequate and are mainly supportive. More efforts need to be devoted to the development of novel pharmacological agents that can prevent viral invasion of cardiac tissue as well as viral- or host-induced inflammation, and reducing arrhythmic complications of the myocarditis.
Statements
Author contributions
GT: Design of manuscript; drafted and critically revised the manuscript for important intellectual content; preparation of figures. JY: Drafted and critically revised the manuscript for important intellectual content. EL: Drafted and critically revised the manuscript for important intellectual content. BY: Interpreted primary research papers; critically revised the manuscript for important intellectual content.
Acknowledgments
GT was awarded a BBSRC Doctoral Training Award and thanks for the Croucher Foundation for its generous support.
Conflict of interest
The authors declare that the research was conducted in the absence of any commercial or financial relationships that could be construed as a potential conflict of interest.
References
1
AhmedM.AlmilajiA.MunozC.ElviraB.ShumilinaE.BockC. T.et al. (2014). Down-regulation of K(+) channels by human parvovirus B19 capsid protein VP1. Biochem. Biophys. Res. Commun.450, 1396–1401. 10.1016/j.bbrc.2014.07.003
2
AhmedM.ElviraB.AlmilajiA.BockC. T.KandolfR.LangF. (2015). Down-regulation of inwardly rectifying Kir2.1 K+ channels by human parvovirus B19 capsid protein VP1. J. Membr. Biol.248, 223–229. 10.1007/s00232-014-9762-9
3
AingerL. E.LawyerN. G.FitchC. W. (1966). Neonatal rubella myocarditis. Br. Heart J.28, 691–697. 10.1136/hrt.28.5.691
4
AlmilajiA.SzteynK.FeinE.PakladokT.MunozC.ElviraB.et al. (2013). Down-regulation of Na/K+ atpase activity by human parvovirus B19 capsid protein VP1. Cell. Physiol. Biochem.31, 638–648. 10.1159/000350083
5
AlterP.GrimmW.MaischB. (2001). Varicella myocarditis in an adult. Heart85:e2. 10.1136/heart.85.1.e2
6
AndreolettiL.LevequeN.BoulagnonC.BrasseletC.FornesP. (2009). Viral causes of human myocarditis. Arch. Cardiovasc. Dis.102, 559–568. 10.1016/j.acvd.2009.04.010
7
AnziniM.MerloM.ArticoJ.SinagraG. (2016). Arrhythmic risk prediction of acute myocarditis presenting with life-threatening ventricular tachyarrhythmias. Int. J. Cardiol.212, 169–170. 10.1016/j.ijcard.2016.03.020
8
ArbustiniE.GrassoM.DiegoliM.PercivalleE.GrossiP.BramerioM.et al. (1992). Histopathologic and molecular profile of human cytomegalovirus infections in patients with heart transplants. Am. J. Clin. Pathol.98, 205–213. 10.1093/ajcp/98.2.205
9
AritaM.UenoY.MasuyamaY. (1981). Complete heart block in mumps myocarditis. Br. Heart J.46, 342–344. 10.1136/hrt.46.3.342
10
Babu-NarayanS. V.McCarthyK. P.HoS. Y.MageeA. G.KilnerP. J.SheppardM. N. (2007). Myocarditis and sudden cardiac death in the young: extensive fibrosis suggested by cardiovascular magnetic resonance in vivo and confirmed post mortem. Circulation116, e122–e125. 10.1161/CIRCULATIONAHA.107.693085
11
BadorffC.LeeG. H.LamphearB. J.MartoneM. E.CampbellK. P.RhoadsR. E.et al. (1999). Enteroviral protease 2A cleaves dystrophin: evidence of cytoskeletal disruption in an acquired cardiomyopathy. Nat. Med.5, 320–326. 10.1038/6543
12
BaksiA. J.KanaganayagamG. S.PrasadS. K. (2015). Arrhythmias in viral myocarditis and pericarditis. Card. Electrophysiol. Clin.7, 269–281. 10.1016/j.ccep.2015.03.009
13
BassoC.CalabreseF.AngeliniA.CarturanE.ThieneG. (2013). Classification and histological, immunohistochemical, and molecular diagnosis of inflammatory myocardial disease. Heart Fail. Rev.18, 673–681. 10.1007/s10741-012-9355-6
14
BelardinelliL.LiuG.Smith-MaxwellC.WangW. Q.El-BizriN.HirakawaR.et al. (2013). A novel, potent, and selective inhibitor of cardiac late sodium current suppresses experimental arrhythmias. J. Pharmacol. Exp. Ther.344, 23–32. 10.1124/jpet.112.198887
15
BergelsonJ. M.CunninghamJ. A.DroguettG.Kurt-JonesE. A.KrithivasA.HongJ. S.et al. (1997). Isolation of a common receptor for Coxsackie B viruses and adenoviruses 2 and 5. Science275, 1320–1323. 10.1126/science.275.5304.1320
16
BiocicS.DurasevicZ.StarcevicB.UdovicicM. (2009). [Varicella zoster myopericarditis in an immunocompetent adult]. Acta Med. Croatica63, 325–327.
17
BowlesN. E.NiJ.KearneyD. L.PauschingerM.SchultheissH. P.McCarthyR.et al. (2003). Detection of viruses in myocardial tissues by polymerase chain reaction. Evidence of adenovirus as a common cause of myocarditis in children and adults. J. Am. Coll. Cardiol.42, 466–472. 10.1016/s0735-1097(03)00648-x
18
BultmannB. D.KlingelK.SotlarK.BockC. T.BabaH. A.SauterM.et al. (2003). Fatal parvovirus B19-associated myocarditis clinically mimicking ischemic heart disease: an endothelial cell-mediated disease. Hum. Pathol.34, 92–95. 10.1053/hupa.2003.48
19
CarusoA.RotolaA.ComarM.FavilliF.GalvanM.TosettiM.et al. (2002). HHV-6 infects human aortic and heart microvascular endothelial cells, increasing their ability to secrete proinflammatory chemokines. J. Med. Virol.67, 528–533. 10.1002/jmv.10133
20
CaseyC. G.IskanderJ. K.RoperM. H.MastE. E.WenX. J.TorokT. J.et al. (2005). Adverse events associated with smallpox vaccination in the United States, January–October 2003. JAMA294, 2734–2743. 10.1001/jama.294.21.2734
21
ChanG.NogalskiM. T.StevensonE. V.YurochkoA. D. (2012). Human cytomegalovirus induction of a unique signalsome during viral entry into monocytes mediates distinct functional changes: a strategy for viral dissemination. J. Leukoc. Biol.92, 743–752. 10.1189/jlb.0112040
22
CheethamH. D.HartJ.CoghillN. F.FoxB. (1970). Rabies with myocarditis. Lancet295, 921–922. 10.1016/S0140-6736(70)91048-2
23
ChenZ.SunB.TseG.JiangJ.XuW. (2016). Reversibility of both sinus node dysfunction and reduced HCN4 mRNA expression level in an atrial tachycardia pacing model of tachycardia-bradycardia syndrome in rabbit hearts. Int. J. Clin. Exp. Pathol.
24
ChimentiC.RussoA.PieroniM.CalabreseF.VerardoR.ThieneG.et al. (2004). Intramyocyte detection of Epstein-Barr virus genome by laser capture microdissection in patients with inflammatory cardiomyopathy. Circulation110, 3534–3539. 10.1161/01.CIR.0000148823.08092.0E
25
ChoyL.YeoJ. M.TseV.ChanS. P.TseG. (2016). Cardiac disease and arrhythmogenesis: mechanistic insights from mouse models. Int. J. Cardiol. Heart. Vasc.12, 1–10. 10.1016/j.ijcha.2016.05.005
26
DeA.MyridakisD.KerriganM.KiblawiF. (2011). Varicella myopericarditis mimicking myocardial infarction in a 17-year-old boy. Tex. Heart Inst. J.38, 288–290.
27
DuncanB. W.BohnD. J.AtzA. M.FrenchJ. W.LaussenP. C.WesselD. L. (2001). Mechanical circulatory support for the treatment of children with acute fulminant myocarditis. J. Thorac. Cardiovasc. Surg.122, 440–448. 10.1067/mtc.2001.115243
28
EisenhutM. (2006). Extrapulmonary manifestations of severe respiratory syncytial virus infection – a systematic review. Crit. Care10, R107. 10.1186/cc4984
29
EloffB. C.LernerD. L.YamadaK. A.SchuesslerR. B.SaffitzJ. E.RosenbaumD. S. (2001). High resolution optical mapping reveals conduction slowing in connexin43 deficient mice. Cardiovasc. Res.51, 681–690. 10.1016/S0008-6363(01)00341-8
30
FelkerG. M.BoehmerJ. P.HrubanR. H.HutchinsG. M.KasperE. K.BaughmanK. L.et al. (2000). Echocardiographic findings in fulminant and acute myocarditis. J. Am. Coll. Cardiol.36, 227–232. 10.1016/S0735-1097(00)00690-2
31
FengqinL.YulinW.XiaoxinZ.YoupengJ.YanC.Qing-qingW.et al. (2010). The heart-protective mechanism of Qishaowuwei formula on murine viral myocarditis induced by CVB3. J. Ethnopharmacol.127, 221–228. 10.1016/j.jep.2009.11.017
32
FungG.LuoH.QiuY.YangD.McManusB. (2016). Myocarditis. Circ. Res.118, 496–514. 10.1161/CIRCRESAHA.115.306573
33
GaaloulI.RiabiS.EvansM.HunterT.HuberS.AouniM. (2016). Postmortem diagnosis of infectious heart diseases: a mystifying cause of Sudden Infant Death. Forensic Sci. Int.262, 166–172. 10.1016/j.forsciint.2016.03.002
34
GaaloulI.RiabiS.HarrathR.EvansM.SalemN. H.MlayehS.et al. (2012). Sudden unexpected death related to enterovirus myocarditis: histopathology, immunohistochemistry and molecular pathology diagnosis at post-mortem. BMC Infect. Dis.12:212. 10.1186/1471-2334-12-212
35
GeorgeS. A.SciutoK. J.LinJ.SalamaM. E.KeenerJ. P.GourdieR. G.et al. (2015). Extracellular sodium and potassium levels modulate cardiac conduction in mice heterozygous null for the Connexin43 gene. Pflugers Arch.467, 2287–2297. 10.1007/s00424-015-1698-0
36
GuerreroP. A.SchuesslerR. B.DavisL. M.BeyerE. C.JohnsonC. M.YamadaK. A.et al. (1997). Slow ventricular conduction in mice heterozygous for a connexin43 null mutation. J. Clin. Invest.99, 1991–1998. 10.1172/JCI119367
37
GuoJ. G. (2008). [Detection of cardiac troponin and high-sensitivity C reactive protein in children with viral myocarditis]. Nan Fang Yi Ke Da Xue Xue Bao28, 1076–1077. 10.1007/s00246-010-9814-6
38
HemidaM. G.YeX.ZhangH. M.HansonP. J.LiuZ.McManusB. M.et al. (2013). MicroRNA-203 enhances coxsackievirus B3 replication through targeting zinc finger protein-148. Cell. Mol. Life Sci.70, 277–291. 10.1007/s00018-012-1104-4
39
HenkeA.JaraschN.MartinU.WegertJ.WildnerA.ZellR.et al. (2008). Recombinant coxsackievirus vectors for prevention and therapy of virus-induced heart disease. Int. J. Med. Microbiol.298, 127–134. 10.1016/j.ijmm.2007.08.010
40
HeymansS. (2006). Inflammation and cardiac remodeling during viral myocarditis. Ernst Schering Res. Found. Workshop55, 197–218. 10.1007/3-540-30822-9_12
41
HsiehY. C.LinJ. C.HungC. Y.LiC. H.LinS. F.YehH. I.et al. (2016). Gap junction modifier rotigaptide decreases the susceptibility to ventricular arrhythmia by enhancing conduction velocity and suppressing discordant alternans during therapeutic hypothermia in isolated rabbit hearts. Heart Rhythm. 13, 251–261. 10.1016/j.hrthm.2015.07.023
42
HsiehY. C.LinS. F.HuangJ. L.HungC. Y.LinJ. C.LiaoY. C.et al. (2014). Moderate hypothermia (33C) decreases the susceptibility to pacing-induced ventricular fibrillation compared with severe hypothermia (30C) by attenuating spatially discordant alternans in isolated rabbit hearts. Acta Cardiol Sin.30, 455–465.
43
HsiehY. C.LinS. F.LinT. C.TingC. T.WuT. J. (2009). Therapeutic hypothermia (30 degrees C) enhances arrhythmogenic substrates, including spatially discordant alternans, and facilitates pacing-induced ventricular fibrillation in isolated rabbit hearts. Circ. J.73, 2214–2222. 10.1253/circj.CJ-09-0432
44
HuangM.BigosD.LevineM. (1998). Ventricular arrhythmia associated with respiratory syncytial viral infection. Pediatr. Cardiol.19, 498–500. 10.1007/s002469900369
45
HughesS. A.ThakerH. M.RacanielloV. R. (2003). Transgenic mouse model for echovirus myocarditis and paralysis. Proc. Natl. Acad. Sci. U.S.A.100, 15906–15911. 10.1073/pnas.2535934100
46
JanuaryC. T.RiddleJ. M.SalataJ. J. (1988). A model for early afterdepolarizations: induction with the Ca2+ channel agonist Bay K 8644. Circ. Res.62, 563–571. 10.1161/01.RES.62.3.563
47
JensenL. D.MarchantD. J. (2016). Emerging pharmacologic targets and treatments for myocarditis. Pharmacol. Ther.161, 40–51. 10.1016/j.pharmthera.2016.03.006
48
JuhaszZ.TiszlaviczL.KeleB.TerhesG.DeakJ.RudasL.et al. (2014). Sudden cardiac death from parvovirus B19 myocarditis in a young man with Brugada syndrome. J. Forensic Leg. Med.25, 8–13. 10.1016/j.jflm.2014.04.018
49
KallianosK.MoraesG. L.OrdovasK. G. (2015). Prognostic role of MR imaging in nonischemic myocardial disease. Magn. Reson. Imaging Clin. N. Am.23, 89–94. 10.1016/j.mric.2014.09.004
50
KarjalainenJ.HeikkilaJ.NieminenM. S.JalankoH.KleemolaM.LapinleimuK.et al. (1983). Etiology of mild acute infectious myocarditis. relation to clinical features. Acta Med. Scand.213, 65–73. 10.1111/j.0954-6820.1983.tb03692.x
51
KindermannI.BarthC.MahfoudF.UkenaC.LenskiM.YilmazA.et al. (2012). Update on Myocarditis. J. Am. Coll. Cardiol.59, 779–792. 10.1016/j.jacc.2011.09.074
52
KrisemanT. (1984). Rubella myocarditis in a 9-year-old patient. Clin. Pediatr.23, 240–241. 10.1177/000992288402300413
53
KühlU.PauschingerM.NoutsiasM.SeebergB.BockT.LassnerD.et al. (2005). High prevalence of viral genomes and multiple viral infections in the myocardium of adults with “idiopathic” left ventricular dysfunction. Circulation111, 887–893. 10.1161/01.CIR.0000155616.07901.35
54
LaakeH. (1951). Myocarditis in Poliomyelitis. Acta Med. Scand.140, 159–169. 10.1111/j.0954-6820.1951.tb10168.x
55
LiaoP.-H.HsuY.-H.YangH.-H.WangM.-H.ChenL.-K. (2012). Involvement of extraneural tissues and upregulation of inducible nitric oxide synthase after experimental infection with rabies virus in BALB/c mice and LEW/SsN rats. Pathol. Int.62, 619–627. 10.1111/j.1440-1827.2012.02846.x
56
LinJ.KeenerJ. P. (2013). Ephaptic coupling in cardiac myocytes. IEEE Trans. Biomed. Eng.60, 576–582. 10.1109/TBME.2012.2226720
57
LinJ.KeenerJ. P. (2014). Microdomain effects on transverse cardiac propagation. Biophys. J.106, 925–931. 10.1016/j.bpj.2013.11.1117
58
LupescuA.BockC. T.LangP. A.AberleS.KaiserH.KandolfR.et al. (2006). Phospholipase A2 Activity-Dependent Stimulation of Ca(2+) Entry by Human Parvovirus B19 Capsid Protein VP1. J. Virol.80, 11370–11380. 10.1128/JVI.01041-06
59
LupescuA.GeigerC.ZahirN.AberleS.LangP. A.KramerS.et al. (2009). Inhibition of Na+/H+ exchanger activity by parvovirus B19 protein NS1. Cell. Physiol. Biochem.23, 211–220. 10.1159/000204110
60
MartinoT. A.PetricM.BrownM.AitkenK.GaunttC. J.RichardsonC. D.et al. (1998). Cardiovirulent coxsackieviruses and the decay-accelerating factor (CD55) receptor. Virology244, 302–314. 10.1006/viro.1998.9122
61
MatsumoriA. (2012). Myocarditis: past, present and future. Kitasato Med. J.42, 3–7.
62
MatsumoriA.YutaniC.IkedaY.KawaiS.SasayamaS. (2000). Hepatitis C virus from the hearts of patients with myocarditis and cardiomyopathy. Lab. Invest.80, 1137–1142. 10.1038/labinvest.3780120
63
MavrogeniS.PetrouE.KolovouG.TheodorakisG.IliodromitisE. (2013). Prediction of ventricular arrhythmias using cardiovascular magnetic resonance. Eur. Heart J. Cardiovasc. Imaging14, 518–525. 10.1093/ehjci/jes302
64
MorleyG. E.VaidyaD.SamieF. H.LoC.DelmarM.JalifeJ. (1999). Characterization of conduction in the ventricles of normal and heterozygous Cx43 knockout mice using optical mapping. J. Cardiovasc. Electrophysiol.10, 1361–1375. 10.1111/j.1540-8167.1999.tb00192.x
65
NeilanT. G.FarhadH.MayrhoferT.ShahR. V.DodsonJ. A.AbbasiS. A.et al. (2015). Late gadolinium enhancement among survivors of sudden cardiac arrest. JACC Cardiovasc. Imaging8, 414–423. 10.1016/j.jcmg.2014.11.017
66
NerbonneJ. M. (2000). Molecular basis of functional voltage-gated K+ channel diversity in the mammalian myocardium. J. Physiol.525, 285–298. 10.1111/j.1469-7793.2000.t01-1-00285.x
67
NiwanoS.HirasawaS.NiwanoH.SasakiS.MasudaR.SatoK.et al. (2012). Cardioprotective effects of sarcolemmal and mitochondrial K-ATP channel openers in an experimental model of autoimmune myocarditis. Role of the reduction in calcium overload during acute heart failure. Int. Heart J.53, 139–145. 10.1536/ihj.53.139
68
OromU. A.NielsenF. C.LundA. H. (2008). MicroRNA-10a binds the 5′UTR of ribosomal protein mRNAs and enhances their translation. Mol. Cell30, 460–471. 10.1016/j.molcel.2008.05.001
69
OsadchiiO. E. (2010). Mechanisms of hypokalemia-induced ventricular arrhythmogenicity. Fundam. Clin. Pharmacol.24, 547–559. 10.1111/j.1472-8206.2010.00835.x
70
OsadchiiO. E. (2014). Impact of hypokalemia on electromechanical window, excitation wavelength and repolarization gradients in guinea-pig and rabbit hearts. PLoS ONE9:e105599. 10.1371/journal.pone.0105599
71
PanH. Y.YamadaH.ChidaJ.WangS.YanoM.YaoM.et al. (2011). Up-regulation of ectopic trypsins in the myocardium by influenza A virus infection triggers acute myocarditis. Cardiovasc. Res.89, 595–603. 10.1093/cvr/cvq358
72
ParkH.ParkH.LeeD.OhS.LimJ.HwangH. J.et al. (2014a). Increased phosphorylation of Ca(2+) handling proteins as a proarrhythmic mechanism in myocarditis. Circ. J.78, 2292–2301. 10.1253/circj.CJ-14-0277
73
ParkH.ParkH.LimJ.OhS.ParkS.PakH. M.et al. (2014b). Arrhythmogenic mechanisms of autoimmune myocarditis associated with inflammation and Ca2+/calmodulin-dependent protein kinase II activation. Int. J. Arrhythm.15, 4–16.
74
PasquiéJ. L. (2005). May Fever Trigger Ventricular Fibrillation?Indian Pacing Electrophysiol. J.5, 139–145.
75
PataneS.MarteF. (2010). Revelation of Brugada electrocardiographic pattern during a febrile state associated with acute myocardial infarction. Int. J. Cardiol.144, e1–e4. 10.1016/j.ijcard.2008.12.037
76
PataneS.MarteF.La RosaF. C.AlbaneseA.La RoccaR.VillariS. A. (2010). Revelation of Brugada electrocardiographic pattern during a febrile state. Int. J. Cardiol.140, e19–e21. 10.1016/j.ijcard.2008.11.069
77
PauschingerM.ChandrasekharanK.SchultheissH. P. (2004). Myocardial remodeling in viral heart disease: possible interactions between inflammatory mediators and MMP-TIMP system. Heart Fail. Rev.9, 21–31. 10.1023/B:HREV.0000011391.81676.3c
78
PetrykaJ.BaksiA. J.PrasadS. K.PennellD. J.KilnerP. J. (2014). Prevalence of inferobasal myocardial crypts among patients referred for cardiovascular magnetic resonance. Circ. Cardiovasc. Imaging7, 259–264. 10.1161/CIRCIMAGING.113.001241
79
PorterH. J.QuantrillA. M.FlemingK. A. (1988). B19 parvovirus infection of myocardial cells. Lancet1, 535–536. 10.1016/S0140-6736(88)91332-3
80
PrioriS. G.CorrP. B. (1990). Mechanisms underlying early and delayed afterdepolarizations induced by catecholamines. Am. J. Physiol.258, H1796–H1805.
81
ReisF. J.VianaM.OliveiraM.SousaT. A.ParanaR. (2007). Prevalence of hepatitis C and B virus infection in patients with idiopathic dilated cardiomyopathy in Brazil: a pilot study. Braz. J. Infect. Dis.11, 318–321. 10.1590/S1413-86702007000300004
82
RezkallaS. H.KlonerR. A. (2010). Influenza-related viral myocarditis. WMJ109, 209–213.
83
RhettJ. M.GourdieR. G. (2012). The perinexus: a new feature of Cx43 gap junction organization. Heart Rhythm9, 619–623. 10.1016/j.hrthm.2011.10.003
84
RhettJ. M.VeeraraghavanR.PoelzingS.GourdieR. G. (2013). The perinexus: sign-post on the path to a new model of cardiac conduction?Trends Cardiovasc. Med.23, 222–228. 10.1016/j.tcm.2012.12.005
85
RichR.McErleanM. (1993). Complete heart block in a child with varicella. Am. J. Emerg. Med.11, 602–605. 10.1016/0735-6757(93)90011-Y
86
RongQ.HuangJ.SuE.LiJ.LiJ.ZhangL.et al. (2007). Infection of hepatitis B virus in extrahepatic endothelial tissues mediated by endothelial progenitor cells. Virol. J.4, 1–14. 10.1186/1743-422X-4-36
87
RosenbergD. H. (1945). Electrocardiographic Changes in Epidemic Parotitis (Mumps). Exp. Biol. Med.58, 9–11. 10.3181/00379727-58-14819
88
RossE.ArmentroutS. A. (1962). Myocarditis Associated with Rabies. N. Engl. J. Med.266, 1087–1089. 10.1056/NEJM196205242662105
89
SaitoJ.NiwanoS.NiwanoH.InomataT.YumotoY.IkedaK.et al. (2002). Electrical remodeling of the ventricular myocardium in myocarditis: studies of rat experimental autoimmune myocarditis. Circ. J.66, 97–103. 10.1253/circj.66.97
90
SalernoF.GirerdN.ChalabreysseL.BillaudG.LinaB.ChevalierP. (2011). Myocarditis and cardiac channelopathies: a deadly association?Int. J. Cardiol.147, 468–470. 10.1016/j.ijcard.2011.01.019
91
SanguinetiF.GarotP.ManaM.O'H-IciD.HovasseT.UnterseehT.et al. (2015). Cardiovascular magnetic resonance predictors of clinical outcome in patients with suspected acute myocarditis. J. Cardiovasc. Magn. Reson.17, 78. 10.1186/s12968-015-0185-2
92
Savio-GalimbertiE.KnollmannB. C. (2015). Channel activity of cardiac ryanodine receptors (RyR2) determines potency and efficacy of flecainide and r-propafenone against arrhythmogenic calcium waves in ventricular cardiomyocytes. PLoS ONE10:e0131179. 10.1371/journal.pone.0131179
93
SavonC.AcostaB.ValdesO.GoyenecheaA.GonzalezG.PinonA.et al. (2008). A myocarditis outbreak with fatal cases associated with adenovirus subgenera C among children from Havana City in 2005. J. Clin. Virol.43, 152–157. 10.1016/j.jcv.2008.05.012
94
ShaboodienG.MaskeC.WainwrightH.SmutsH.NtsekheM.CommerfordP. J.et al. (2013). Prevalence of myocarditis and cardiotropic virus infection in Africans with HIV-associated cardiomyopathy, idiopathic dilated cardiomyopathy and heart transplant recipients: a pilot study: cardiovascular topic. Cardiovasc. J. Afr.24, 218–223. 10.5830/CVJA-2013-039
95
ShimizuW.AibaT.KamakuraS. (2005). Mechanisms of disease: current understanding and future challenges in Brugada syndrome. Nat. Clin. Pract. Cardiovasc. Med.2, 408–414. 10.1038/ncpcardio0268
96
SipidoK. R.VarroA.EisnerD. (2006). Sodium calcium exchange as a target for antiarrhythmic therapy. Handb. Exp. Pharmacol.171, 159–199. 10.1007/3-540-29715-4_6
97
SmeetsJ. L.AllessieM. A.LammersW. J.BonkeF. I.HollenJ. (1986). The wavelength of the cardiac impulse and reentrant arrhythmias in isolated rabbit atrium. The role of heart rate, autonomic transmitters, temperature, and potassium. Circ. Res.58, 96–108. 10.1161/01.RES.58.1.96
98
SongX.LiuZ.WangH.XinY.WangX.ChenJ.et al. (2007). QiHong prevents death in coxsackievirus B3 induced murine myocarditis through inhibition of virus attachment and penetration. Exp. Biol. Med. (Maywood)232, 1441–1448. 10.3181/0704-RM-110
99
SprayD. C.BurtJ. M. (1990). Structure-activity relationships of the cardiac gap junction channel. Am. J. Physiol.258, C195–C205.
100
SteinM.van VeenT. A.HauerR. N.de BakkerJ. M.van RijenH. V. (2011). A 50% reduction of excitability but not of intercellular coupling affects conduction velocity restitution and activation delay in the mouse heart. PLoS ONE6:e20310. 10.1371/journal.pone.0020310
101
SteinM.van VeenT. A.RemmeC. A.BoulaksilM.NoormanM.van StuijvenbergL.et al. (2009). Combined reduction of intercellular coupling and membrane excitability differentially affects transverse and longitudinal cardiac conduction. Cardiovasc. Res.83, 52–60. 10.1093/cvr/cvp124
102
SteinbergerJ.LucasR. V.Jr.EdwardsJ. E.TitusJ. L. (1996). Causes of sudden unexpected cardiac death in the first two decades of life. Am. J. Cardiol.77, 992–995. 10.1016/S0002-9149(96)00035-5
103
SteinkeK.SachseF.EttischerN.Strutz-SeebohmN.HenrionU.RohrbeckM.et al. (2013). Coxsackievirus B3 modulates cardiac ion channels. FASEB J.27, 4108–4121. 10.1096/fj.13-230193
104
StraussD. G.WuK. C. (2009). Imaging myocardial scar and arrhythmic risk prediction–a role for the electrocardiogram?J. Electrocardiol.42, 138 e131–138 e138. 10.1016/j.jelectrocard.2008.12.010
105
TangQ.HuangJ.QianH.ChenL.WangT.WangH.et al. (2007). Antiarrhythmic effect of atorvastatin on autoimmune myocarditis is mediated by improving myocardial repolarization. Life Sci.80, 601–608. 10.1016/j.lfs.2006.11.045
106
TavoraF.Gonzalez-CuyarL. F.DalalJ. S.O'MalleyM. T.ZhaoR.PengH. Q.et al. (2008). Fatal parvoviral myocarditis: a case report and review of literature. Diagn. Pathol.3, 1–6. 10.1186/1746-1596-3-21
107
ThomasS. A.SchuesslerR. B.BerulC. I.BeardsleeM. A.BeyerE. C.MendelsohnM. E.et al. (1998). Disparate effects of deficient expression of connexin43 on atrial and ventricular conduction: evidence for chamber-specific molecular determinants of conduction. Circulation97, 686–691. 10.1161/01.CIR.97.7.686
108
TomariY.ZamoreP. D. (2005). Perspective: machines for RNAi. Genes Dev.19, 517–529. 10.1101/gad.1284105
109
TominagaM.MatsumoriA.HorieM.YoshidaH.OkadaY. (1993). Activation of Ca-permeable cation channels by myocarditis-associated antibody in guinea pig ventricular myocytes. J. Clin. Invest.91, 1231–1234. 10.1172/JCI116285
110
TongL.LinL.WuS.GuoZ.WangT.QinY.et al. (2013). MiR-10a* up-regulates coxsackievirus B3 biosynthesis by targeting the 3D-coding sequence. Nucleic Acids Res.41, 3760–3771. 10.1093/nar/gkt058
111
TseG. (2015). Mechanisms of Cardiac Arrhythmias. J. Arrhythm.32, 75–81. 10.1016/j.joa.2015.11.003
112
TseG. (2016a). Both transmural dispersion of repolarization and transmural dispersion of refractoriness are poor predictors of arrhythmogenicity: A role for the index of Cardiac Electrophysiological Balance (QT/QRS)?J. Geriatr. Cardiol.
113
TseG. (2016b). Novel conduction-repolarization indices for the stratification of arrhythmic risk. J. Geriatr. Cardiol.
114
TseG. (2016c). (Tpeak-Tend)/QRS and (Tpeak-Tend)/(QT x QRS): novel markers for predicting arrhythmic risk in Brugada syndrome. Europace. 10.17863/CAM.113
115
TseG.AliA.AlpenduradaF.PrasadS.RaphaelC. E.VassiliouV. (2015a). Tuberculous constrictive pericarditis. Res. Cardiovasc. Med.4:e29614. 10.5812/cardiovascmed.29614
116
TseG.AliA.PrasadS. K.VassiliouV.RaphaelC. E. (2015b). Atypical case of post-partum cardiomyopathy: an overlap syndrome with arrhythmogenic right ventricular cardiomyopathy?BJR Case Rep.1, 20150182. 10.1259/bjrcr.20150182
117
TseG.HothiS. S.GraceA. A.HuangC. L. (2012). Ventricular arrhythmogenesis following slowed conduction in heptanol-treated, Langendorff-perfused mouse hearts. J. Physiol. Sci.62, 79–92. 10.1007/s12576-011-0187-2
118
TseG.LaiE. T.LeeA. P.YanB. P.WongS. H. (2016a). Electrophysiological mechanisms of gastrointestinal arrhythmogenesis: lessons from the heart. Front. Physiol.7:230. 10.3389/fphys.2016.00230
119
TseG.LaiE. T.TseV.YeoJ. M. (2016b). Molecular and electrophysiological mechanisms underlying cardiac arrhythmogenesis in diabetes mellitus. J. Diabetes Res.
120
TseG.LaiE. T.YeoJ. M.YanB. P. (2016c). Electrophysiological mechanisms of Bayés syndrome: insights from clinical and mouse studies. Front. Physiol.7:188. 10.3389/fphys.2016.00188
121
TseG.LaiT. H.YeoJ. M.TseV.WongS. H. (2016d). Mechanisms of electrical activation and conduction in the gastrointestinal system: lessons from cardiac electrophysiology. Front. Physiol.7:182. 10.3389/fphys.2016.00182
122
TseG.SunB.WongS. T.TseV.YeoJ. M. (2016e). Ventricular anti-arrhythmic effects of hypercalcaemia treatment in hyperkalaemic, Langendorff-perfused mouse hearts. Biomed. Rep.10.3892/br.2016.577
123
TseG.TseV.YeoJ. M. (2016f). Ventricular anti-arrhythmic effects of heptanol in hypokalaemic, Langendorff-perfused mouse hearts. Biomed Rep.4, 313–324. 10.3892/br.2016.577
124
TseG.TseV.YeoJ. M.SunB. (2016g). Atrial anti-arrhythmic effects of heptanol in Langendorff-perfused mouse hearts. PLoS ONE.11:e0148858. 10.1371/journal.pone.0148858
125
TseG.WongS. T.TseV.YeoJ. M. (2016h). Depolarization vs. repolarization: what is the mechanism of ventricular arrhythmogenesis underlying sodium channel haploinsufficiency in mouse hearts?Acta Physiol (Oxf). [Epub ahead of print]. 10.1111/apha.12694
126
TseG.WongS. T.TseV.YeoJ. M. (2016i). Determination of action potential wavelength restitution in Scn5a+/− mouse hearts modelling human Brugada syndrome. J. Physiol.
127
TseG.WongS. T.TseV.YeoJ. M. (2016j). Monophasic action potential recordings: which is the recording electrode?J. Basic Clin. Physiol. Pharmacol. [Epub ahead of print]. 10.1515/jbcpp-2016-0007
128
TseG.WongS. T.TseV.YeoJ. M. (2016k). Restitution analysis of alternans using dynamic pacing and its comparison with S1S2 restitution in heptanol-treated, hypokalaemic Langendorff-perfused mouse hearts. Biomed. Rep.4, 673–680. 10.3892/br.2016.659
129
TseG.WongS. T.TseV.YeoJ. M. (2016l). Variability in local action potential durations, dispersion of repolarization and wavelength restitution in aged wild-type and Scn5a+/− mouse hearts modelling human Brugada syndrome. J. Geriatr. Cardiol.
130
TseG.WongS. T. T. V.LeeY. T.LinH. Y.YeoJ. M. (2016m). Cardiac dynamics: alternans and arrhythmogenesis. J. Arrhythm. 10.1016/j.joa.2016.02.009
131
TseG.YanB. P. (2016a). Novel arrhythmic risk markers incorporating QRS dispersion: QRSd x (Tpeak-Tend) / QRS and QRSd x (Tpeak-Tend) / (QT x QRS). Ann. Noninvasive Electrocardiol.
132
TseG.YanB. P. (2016b). Traditional and novel electrocardiographic markers for predicting arrhythmic risk and sudden cardiac death. Europace.
133
TseG.YanB. P.ChanY. W.TianX. Y.HuangY. (2016n). Reactive oxygen species, endoplasmic reticulum stress and mitochondrial dysfunction: the link with cardiac arrhythmogenesis. Front. Physiol.7:313. 10.3389/fphys.2016.00313
134
TseG.YeoJ. M. (2015). Conduction abnormalities and ventricular arrhythmogenesis: the roles of sodium channels and gap junctions. Int. J. Cardiol. Heart Vasc.9, 75–82. 10.1016/j.ijcha.2015.10.003
135
TseG.YeoJ. M.TseV.SunB. (2016o). Gap junction inhibition by heptanol increases ventricular arrhythmogenicity by decreasing conduction velocity without affecting repolarization properties or myocardial refractoriness in Langendorff-perfused mouse hearts. Mol. Med. Rep.
136
UkimuraA.SatomiH.OoiY.KanzakiY. (2012). Myocarditis associated with influenza A H1N1pdm2009. Influenza Res. Treat.2012, 8. 10.1155/2012/351979
137
VaidyaD.MorleyG. E.SamieF. H.JalifeJ. (1999). Reentry and fibrillation in the mouse heart. A challenge to the critical mass hypothesis. Circ. Res.85, 174–181. 10.1161/01.RES.85.2.174
138
VaidyaD.TamaddonH. S.LoC. W.TaffetS. M.DelmarM.MorleyG. E.et al. (2001). Null mutation of connexin43 causes slow propagation of ventricular activation in the late stages of mouse embryonic development. Circ. Res.88, 1196–1202. 10.1161/hh1101.091107
139
ValdesO.AcostaB.PinonA.SavonC.GoyenecheaA.GonzalezG.et al. (2008). First report on fatal myocarditis associated with adenovirus infection in Cuba. J. Med. Virol.80, 1756–1761. 10.1002/jmv.21274
140
van RijenH. V.EckardtD.DegenJ.TheisM.OttT.WilleckeK.et al. (2004). Slow conduction and enhanced anisotropy increase the propensity for ventricular tachyarrhythmias in adult mice with induced deletion of connexin43. Circulation109, 1048–1055. 10.1161/01.CIR.0000117402.70689.75
141
VassiliouV.ChinC.PerperoglouA.TseG.AliA.RaphaelC.et al. (2014). 93 Ejection fraction by cardiovascular magnetic resonance predicts adverse outcomes post aortic valve replacement. Heart100, A53–A54. 10.1136/heartjnl-2014-306118.93
142
VeeraraghavanR.LinJ.HoekerG. S.KeenerJ. P.GourdieR. G.PoelzingS. (2015). Sodium channels in the Cx43 gap junction perinexus may constitute a cardiac ephapse: an experimental and modeling study. Pflugers Arch.467, 2093–2105. 10.1007/s00424-014-1675-z
143
VeeraraghavanR.PoelzingS.GourdieR. G. (2014a). Intercellular electrical communication in the heart: a new, active role for the intercalated disk. Cell Commun. Adhes.21, 161–167. 10.3109/15419061.2014.905932
144
VeeraraghavanR.PoelzingS.GourdieR. G. (2014b). Novel ligands for zipping and unzipping the intercalated disk: today's experimental tools, tomorrow's therapies?Cardiovasc. Res.104, 229–230. 10.1093/cvr/cvu216
145
VeeraraghavanR.PoelzingS.GourdieR. G. (2014c). Old cogs, new tricks: a scaffolding role for connexin43 and a junctional role for sodium channels?FEBS Lett.588, 1244–1248. 10.1016/j.febslet.2014.01.026
146
VeeraraghavanR.SalamaM. E.PoelzingS. (2012). Interstitial volume modulates the conduction velocity-gap junction relationship. Am. J. Physiol. Heart Circ. Physiol.302, H278–H286. 10.1152/ajpheart.00868.2011
147
Venkat RamanG.ProsserA.SpreadburyP. L.CockcroftP. M.OkubadejoO. A. (1988). Rabies presenting with myocarditis and encephalitis. J. Infect.17, 155–158. 10.1016/S0163-4453(88)91767-7
148
WakisakaY.NiwanoS.NiwanoH.SaitoJ.YoshidaT.HirasawaS.et al. (2004). Structural and electrical ventricular remodeling in rat acute myocarditis and subsequent heart failure. Cardiovasc. Res.63, 689–699. 10.1016/j.cardiores.2004.04.020
149
WoolfP. K.ChungT. S.StewartJ.LialiosM.DavidianM.GewitzM. H. (1987). Life-threatening dysrhythmias in varicella myocarditis. Clin. Pediatr. (Phila)26, 480–482. 10.1177/000992288702600911
150
XuH. F.DingY. J.ShenY. W.XueA. M.XuH. M.LuoC. L.et al. (2012). MicroRNA- 1 represses Cx43 expression in viral myocarditis. Mol. Cell. Biochem.362, 141–148. 10.1007/s11010-011-1136-3
151
YeX.HemidaM. G.QiuY.HansonP. J.ZhangH. M.YangD. (2013). MiR-126 promotes coxsackievirus replication by mediating cross-talk of ERK1/2 and Wnt/beta-catenin signal pathways. Cell. Mol. Life Sci.70, 4631–4644. 10.1007/s00018-013-1411-4
152
YoshikawaT.IhiraM.SuzukiK.SugaS.KitoH.IwasakiT.et al. (2001). Fatal acute myocarditis in an infant with human herpesvirus 6 infection. J. Clin. Pathol.54, 792–795. 10.1136/jcp.54.10.792
Summary
Keywords
viral myocarditis, cardiac arrhythmia, mouse model, viral-induced cardiomyopathy, conduction, repolarization
Citation
Tse G, Yeo JM, Chan YW, Lai ETHL and Yan BP (2016) What Is the Arrhythmic Substrate in Viral Myocarditis? Insights from Clinical and Animal Studies. Front. Physiol. 7:308. doi: 10.3389/fphys.2016.00308
Received
07 June 2016
Accepted
06 July 2016
Published
21 July 2016
Volume
7 - 2016
Edited by
Gaetano Santulli, Columbia University, USA
Reviewed by
Richard David Walton, Université Bordeaux Segalen, France; Bozena Werner, Medical University of Warsaw, Poland
Updates
Copyright
© 2016 Tse, Yeo, Chan, Lai and Yan.
This is an open-access article distributed under the terms of the Creative Commons Attribution License (CC BY). The use, distribution or reproduction in other forums is permitted, provided the original author(s) or licensor are credited and that the original publication in this journal is cited, in accordance with accepted academic practice. No use, distribution or reproduction is permitted which does not comply with these terms.
*Correspondence: Gary Tse gary.tse@doctors.org.uk
This article was submitted to Cardiac Electrophysiology, a section of the journal Frontiers in Physiology
Disclaimer
All claims expressed in this article are solely those of the authors and do not necessarily represent those of their affiliated organizations, or those of the publisher, the editors and the reviewers. Any product that may be evaluated in this article or claim that may be made by its manufacturer is not guaranteed or endorsed by the publisher.